Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders

被引:81
|
作者
Ye, Na [1 ,2 ]
Neumeyer, John L. [3 ]
Baldessarini, Ross J. [4 ]
Zhen, Xuechu [5 ]
Zhang, Ao [1 ,2 ]
机构
[1] Chinese Acad Sci, SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, SIMM, SOMCL, Shanghai 201203, Peoples R China
[3] Harvard Med Sch, McLean Hosp, Med Chem Lab, Belmont, MA 02478 USA
[4] McLean Hosp, Psychopharmacol Program, Belmont, MA 02478 USA
[5] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215123, Peoples R China
基金
美国国家科学基金会;
关键词
PRELIMINARY PHARMACOLOGICAL EVALUATION; IN-VITRO BINDING; POSITRON-EMISSION-TOMOGRAPHY; SUBSTITUTED PIPERIDINE NAPHTHAMIDES; NONAROMATIC CATECHOL BIOISOSTERES; STRUCTURE-AFFINITY RELATIONSHIPS; ATYPICAL ANTIPSYCHOTIC AGENTS; ASYMMETRIC CONJUGATE ADDITION; FUNCTIONALIZED LINKING CHAINS; HETEROCYCLIC RING-SYSTEMS;
D O I
10.1021/cr300113a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Dopamine (DA) is a critical neurotransmitter in the mammalian central nervous system (CNS). The cerebral dopaminergic system is implicated in the pathophysiology of several neurobehavioral disorders, including Parkinson's disease and other movement and hyperactivity disorders. The mesocortical system is a neural pathway connecting the ventral tegmentum of midbrain to the cerebral cortex, particularly the mesioprefontal lobes. It is essential to the normal cognitive function of the dorsolateral prefrontal cortex and involved in motivation and emotional response. The mesolimbic system is one of the neural pathways in the brain linking the ventral tegmental area (VTA) to the nucleus accumbens septi (NAS) in the limbic system. DA receptors belong to a superfamily of large proteins characterized by having seven relatively hydrophobic segments that are assumed to be cell-membrane spanning. They are coupled to G proteins that interact with several membrane or cytoplasmic effector molecules (usually enzymes, transporters, or ion channels) that regulate neuronal functions.
引用
收藏
页码:PR123 / PR177
页数:55
相关论文
共 22 条
  • [1] Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders
    Zhang, Ao
    Neumeyer, John L.
    Baldessarini, Ross J.
    CHEMICAL REVIEWS, 2007, 107 (01) : 274 - 302
  • [2] Development of subtype-selective oestrogen receptor-based therapeutics
    Stefan Nilsson
    Konrad F. Koehler
    Jan-Åke Gustafsson
    Nature Reviews Drug Discovery, 2011, 10 : 778 - 792
  • [3] Development of subtype-selective oestrogen receptor-based therapeutics
    Nilsson, Stefan
    Koehler, Konrad F.
    Gustafsson, Jan-Ake
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (10) : 778 - 792
  • [4] Development of subtype-selective nicotinic receptor ligands as receptor antagonists at the dopamine-releasing receptor subtype.
    Crooks, PA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U911 - U911
  • [5] Subtype-Selective Dopamine Receptor Radioligands for PET Imaging: Current Status and Recent Developments
    Banerjee, A.
    Prante, O.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (23) : 3957 - 3966
  • [6] The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents
    Lloyd, GK
    Menzaghi, F
    Bontempi, B
    Suto, C
    Siegel, R
    Akong, M
    Stauderman, K
    Velicelebi, G
    Johnson, E
    Harpold, MM
    Rao, TS
    Sacaan, AI
    Chavez-Noriega, LE
    Washburn, MS
    Vernier, JM
    Cosford, NDP
    McDonald, LA
    LIFE SCIENCES, 1998, 62 (17-18) : 1601 - 1606
  • [7] Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents
    Dwoskin, LP
    Sumithran, SP
    Zhu, J
    Deaciuc, AG
    Ayers, JT
    Crooks, PA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (08) : 1863 - 1867
  • [8] Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders
    Luedtke, RR
    Mach, RH
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (08) : 643 - 671
  • [9] Recent Progress in the Development of Subtype Selective Nicotinic Acetylcholine Receptor Ligands
    Astles, P. C.
    Baker, S. R.
    Boot, J. R.
    Broad, L. M.
    Dell, C. P.
    Keenan, M.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (04) : 337 - 348
  • [10] Structure-based development of a subtype-selective orexin 1 receptor antagonist
    Hellmann, Jan
    Drabek, Matthaeus
    Yin, Jie
    Gunera, Jakub
    Proell, Theresa
    Kraus, Frank
    Langmead, Christopher J.
    Huebner, Harald
    Weikert, G. Dorothee
    Kolb, Peter
    Rosenbaum, Daniel M.
    Gmeiner, Peter
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (30) : 18059 - 18067